Cargando…
Baclofen to Prevent Relapse in Gamma-Hydroxybutyrate (GHB)-Dependent Patients: A Multicentre, Open-Label, Non-Randomized, Controlled Trial
BACKGROUND: Gamma-hydroxybutyrate (GHB) dependence is associated with a severe, potentially lethal, withdrawal syndrome and relapse rates as high as 60% within 3 months of detoxification. Baclofen has been shown to decrease self-administration of GHB in mice and reduce relapse in a case series of GH...
Autores principales: | Beurmanjer, Harmen, Kamal, Rama M., de Jong, Cor A. J., Dijkstra, Boukje A. G., Schellekens, Arnt F. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976688/ https://www.ncbi.nlm.nih.gov/pubmed/29651711 http://dx.doi.org/10.1007/s40263-018-0516-6 |
Ejemplares similares
-
Baclofen as relapse prevention in the treatment of Gamma- Hydroxybutyrate (GHB) dependence: an open label study
por: Kamal, Rama M, et al.
Publicado: (2015) -
Characterization of the GHB Withdrawal Syndrome
por: Wolf, Casper J. H., et al.
Publicado: (2021) -
Gamma-Hydroxybutyrate (GHB) With-Drawal
por: Everett, Worth
Publicado: (2001) -
Tapering with Pharmaceutical GHB or Benzodiazepines for Detoxification in GHB-Dependent Patients: A Matched-Subject Observational Study of Treatment-as-Usual in Belgium and The Netherlands
por: Beurmanjer, Harmen, et al.
Publicado: (2020) -
Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse
por: Tay, Emma, et al.
Publicado: (2022)